Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.
Purpose: To summarize the evidence of efficacy and safety of the use of ketamine and esketamine for depression. Methods: A literature search was performed in Medline, the Cochrane Library, LILACS, and CRD until November 2020. We included systematic reviews with meta-analyses of randomized controlled...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 78; no. 3; pp. 311 - 339 |
|---|---|
| Autores principales: | , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Springer Nature
Mar2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155080936&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155080936 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Mar2022 vid: 78 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 155080936 153261121 155080936 155080936 10.1007/s00228-021-03216-8 155080936 ppf: 311 ppct: 28 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. aug: au: Lima, Tácio de Mendonça Visacri, Marília Berlofa Aguiar, Patricia Melo affil: Department of Pharmaceutical Sciences, Federal Rural University of Rio de Janeiro, Seropédica, RJ, Brazil sug: subj: Ketamine Therapeutic Use Hallucinogens Therapeutic Use Depression Drug Therapy Patient Safety Drug Efficacy Human Systematic Review Meta Analysis Medline Cochrane Library Treatment Outcomes Disease Remission Adult PubMed Adult: 19-44 years ab: Purpose: To summarize the evidence of efficacy and safety of the use of ketamine and esketamine for depression. Methods: A literature search was performed in Medline, the Cochrane Library, LILACS, and CRD until November 2020. We included systematic reviews with meta-analyses of randomized controlled trials on the use of ketamine and esketamine in adult patients with depression. Two authors independently performed the study selection and data extraction. The AMSTAR-2 tool was used to appraise the quality of included reviews. Results: A total of 118 records were identified, and 11 studies fully met the eligibility criteria. Compared to control, ketamine improved the clinical response at 40 min to 1 week and clinical remission at 80 min to 72 h, and esketamine improved both outcomes at 2 h to 4 weeks. Ketamine and esketamine also had a beneficial effect on the depression scales score and suicidality. For adverse events, oral ketamine did not show significant change compared to control, while intranasal esketamine showed difference for any events, such as dissociation, dizziness, hypoesthesia, and vertigo. Most reviews were classified as "critically low quality," and none of them declared the source of funding of the primary studies and assessed the potential impact of risk of bias in primary studies. Conclusion: Ketamine and esketamine showed a significant antidepressant action within a few hours or days after administration; however, the long-term efficacy and safety are lacking. In addition, the methodological quality of the reviews was usually critically low, which may indicate the need for higher quality evidence in relation to the theme. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|